The “Watchman” device is an alternative for patients with non-valvular atrial fibrillation at risk for stroke, especially those with a compelling reason not to be on blood thinners.

ALBUQUERQUE, N.M. (KRQE) – The Lovelace Heart Hospital is celebrating the new addition of their 1,000th heart device. Called ...

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

The WATCHMAN FLX device showed superior safety with 8.5% major bleeding ... for stroke risk reduction in patients with ...

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

Boston Scientific has reported positive three-year data from the OPTION global trial of the WATCHMAN FLX left atrial appendage closure (LAAC) device in individuals with atrial fibrillation ...

Due to the risk of atrial fibrillation recurrence following ... In the trial, approximately 60% of device patients had their WATCHMAN FLX implant 90-180 days following their ablation procedure.